Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Borner

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Oncology Reports|March 10, 2005
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancerUllrich Graeven, Karsten Ridwelski, Maja Artandi, et al.
American Journal of Clinical Pathology|October 16, 2008
Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomasEva Karamitopoulou, Luigi Tornillo, Inti Zlobec, et al.
The Oncologist|November 2, 2010
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I studyJean-François Dufour, Hanno Hoppe, Markus H Heim, et al.
Oncology Research and Treatment|August 5, 2021
Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement ArticleAlexander R Siebenhüner, Sara De Dosso, Daniel Helbling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer ResearchDieter Koeberle, Piercarlo Saletti, Markus Borner, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 10, 2009
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?Karin Ribi, Dieter Koeberle, Jan C Schuller, et al.
Plos One|May 27, 2016
Assessing Rotation-Invariant Feature Classification for Automated Wildebeest Population CountsColin J Torney, Andrew P Dobson, Felix Borner, et al.
Journal of Translational Medicine|April 1, 2014
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survivalViktor H Koelzer, Alessandro Lugli, Heather Dawson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2010
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancerEva Karamitopoulou, Pierlorenzo Pallante, Inti Zlobec, et al.
The Oncologist|March 6, 2010
Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)Dieter Koeberle, Michael Montemurro, Panagiotis Samaras, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Oncology Reports|March 10, 2005
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancerUllrich Graeven, Karsten Ridwelski, Maja Artandi, et al.
American Journal of Clinical Pathology|October 16, 2008
Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomasEva Karamitopoulou, Luigi Tornillo, Inti Zlobec, et al.
The Oncologist|November 2, 2010
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I studyJean-François Dufour, Hanno Hoppe, Markus H Heim, et al.
Oncology Research and Treatment|August 5, 2021
Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement ArticleAlexander R Siebenhüner, Sara De Dosso, Daniel Helbling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer ResearchDieter Koeberle, Piercarlo Saletti, Markus Borner, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 10, 2009
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?Karin Ribi, Dieter Koeberle, Jan C Schuller, et al.
Plos One|May 27, 2016
Assessing Rotation-Invariant Feature Classification for Automated Wildebeest Population CountsColin J Torney, Andrew P Dobson, Felix Borner, et al.
Journal of Translational Medicine|April 1, 2014
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survivalViktor H Koelzer, Alessandro Lugli, Heather Dawson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2010
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancerEva Karamitopoulou, Pierlorenzo Pallante, Inti Zlobec, et al.
The Oncologist|March 6, 2010
Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)Dieter Koeberle, Michael Montemurro, Panagiotis Samaras, et al.
Pageof 5